Pharmaceutical Manufacturing Is Now a Board-Level Priority: Why Capacity Has Become the Defining Competitive Advantage of 2026

SEO Keywords: pharmaceutical manufacturing strategic priority 2026, manufacturing competitive advantage pharma, biologics manufacturing capacity investment, pharma reshoring onshoring US manufacturing, CDMO UK expansion single-use bioreactors, pharma supply chain resilience board level, Fujifilm Biotechnologies Teesside UK, Kindeva Loughborough UK CDMO, pharma manufacturing investment billions, single-use bioreactor biologics CDMO, pharmaceutical manufacturing strategy 2026

Something has changed at the very top of the pharmaceutical industry, and it has changed fast. Manufacturing capacity, once treated primarily as an operational function managed by plant directors and supply chain teams reporting several layers below board level, has migrated upward into the strategic core of pharmaceutical company governance. In 2025 and accelerating into 2026, the decisions that define competitive position in the pharmaceutical industry are increasingly decisions about where medicines are made, who makes them, with what technology, and at what scale. These are now the questions that CEOs, boards, and investors are demanding answers to before they commit capital.

The evidence for this shift is no longer circumstantial. It is visible in the scale of financial commitments being made, in the specific language that Bain and Company, the most closely watched strategy adviser to the global pharmaceutical industry, chose to publish in its 2026 pharmaceutical M&A report, and in the physical infrastructure being built across the UK, Europe, and the United States right now.

The Numbers That Define a Strategic Shift

‍Major pharmaceutical companies collectively announced more than $370 billion in US manufacturing investments over the next five years, according to a Q4 2025 market trend report from DPR Construction, a major contractor and construction manager that counts Eli Lilly, Pfizer, Johnson and Johnson, Merck, Novartis, and Roche among its clients. Michael Marston, life sciences core market co-leader at DPR, told PharmaVoice in November 2025 that in 35 years in the industry, he had never seen the manufacturing investment environment "as hot as it is right now."

The individual company commitments that underpin this aggregate figure are themselves extraordinary in scale. Johnson and Johnson pledged $55 billion in US manufacturing and R&D over four years, a 25% increase over the preceding four years, including three new manufacturing facilities and the groundbreaking of a site in North Carolina. Eli Lilly committed $27 billion to building four new US pharmaceutical manufacturing sites as part of a broader $50 billion US investment since 2020, including facilities for API production and injectable therapies. Merck started construction in October 2025 on a $3 billion, 400,000 square foot pharmaceutical manufacturing facility in Virginia and separately began a $1 billion, 470,000 square foot biologics Center of Excellence in Wilmington, Delaware, designed to house manufacturing and laboratory capabilities for biologics including antibody-drug conjugates and its $29.5 billion-revenue cancer immunotherapy Keytruda. AstraZeneca announced a $50 billion US investment through 2030 inclusive of a new facility in Virginia. Novartis, Roche, Sanofi, GSK, Bristol-Myers Squibb, AbbVie, and Gilead each made comparable commitments, with the combined pledges from the largest global pharmaceutical companies reaching more than $480 billion by late 2025, according to analysis published in Think Global Health.

These numbers are not solely or even primarily a response to the threat of US tariffs on pharmaceutical products, although the Trump administration's trade policy has undeniably accelerated timelines and scale. They also reflect a deeper strategic recognition that has been building in pharmaceutical boardrooms since the COVID-19 pandemic exposed the consequences of over-reliance on globally fragmented, just-in-time manufacturing networks. Supply chain resilience, once a technical concern, became a patient safety concern, a political liability, and ultimately a measure of whether a pharmaceutical company could be trusted to deliver the therapies it had developed.

The Bain Diagnosis: Manufacturing Is Now Competitive Strategy

‍The clearest articulation of this shift in strategic framing came from Bain and Company in its 2026 pharmaceutical M&A report. The firm's strategic advice to pharmaceutical executives was explicit: "Treat manufacturing and supply control as a core source of competitive advantage. Building or buying capacity is no longer operational insurance; it is a strategic move that can define future market leadership."

Bain identified a specific pattern in the 2025 M&A data that validates this framing. In the GLP-1 and incretin therapy space, the most commercially contested drug category of the decade, buyers' strategic focus has shifted from acquiring speed-to-market injectable products to acquiring control over next-generation delivery platforms and manufacturing capacity. The logic is direct: the company that controls manufacturing infrastructure for the next generation of obesity therapies, ADCs, and cell and gene therapies will determine who can supply, who can launch, and at what price. More than 80% of radiopharmaceutical deals in 2025 included manufacturing or isotope supply integration, a figure Bain cited as a "clear shift from pipeline expansion to capacity security." Strategic pharma deal value through November 15, 2025 rose 79% compared with the same period in 2024, with the average deal size rising by more than 80%.

Professional services firm BPM was equally direct in its 2026 life sciences outlook: "Supply chain resilience is no longer just a back-office concern but a board-level priority for life sciences companies, particularly as regulatory scrutiny and geopolitical trade dynamics introduce uncertainty into global manufacturing strategies." BPM argued that "organisations that can demonstrate agile, redundant, and compliant manufacturing capabilities will be better positioned to commercialise their pipelines successfully."

Deloitte's 2026 life sciences outlook confirmed that only 41% of life sciences executives felt optimistic about the global economic outlook, with geopolitical tensions, inflation, and supply chain risks ranking among the chief concerns weighing on strategic planning. From ZS Associates' survey of 115 US-based technology executives from multinational pharmaceutical and biotech firms, 57% expected to see strong returns in the year ahead from AI and analytics tools that specifically reduce stockouts and improve demand forecasting, and one in three planned to automate entire manufacturing workflows through intelligent agents. The same survey noted that companies were "moving decisively to rebalance manufacturing footprints by regionalising supply chains to strengthen resilience and proximity to markets."

Why the Shift Is Happening Now: Four Converging Forces

‍The elevation of manufacturing to board-level strategic priority is not the product of a single development but of four forces converging simultaneously.

First, supply chain fragility has been quantified. The COVID-19 pandemic revealed that 72% of active pharmaceutical ingredient suppliers for the US market were located outside the country, with India and China accounting for 43% and 45% respectively of global API Drug Master File filings in 2024 (compared with the US at 3% and the EU at 6%), down sharply from the US's 23% share and Europe's 63% share in the early 1980s. The dependence created during that period of cost-optimised, globally distributed manufacturing was exposed as a structural vulnerability when supply chains seized up in 2020 and again during subsequent disruptions including the Red Sea shipping crisis, which saw certain shipping routes increase in cost by five-fold when Houthi attacks forced cargo rerouting around southern Africa. These are no longer theoretical risks. They are documented, costed, and politically visible failures with direct patient impact.

Second, the BIOSECURE Act has fundamentally altered the risk assessment of Chinese CDMO dependency. As covered in detail in our earlier blog on the biologics CDMO market, the BIOSECURE Act signed into US law in December 2025 creates legal and compliance risk for pharmaceutical companies that rely on certain Chinese biotechnology companies for manufacturing services. With 79% of biopharmaceutical companies having some product or contract with a Chinese CMO or CDMO, and WuXi AppTec alone involved in the production of an estimated quarter of drugs used in the United States, the legislation has forced boards to directly address manufacturing geography as a legal compliance matter, not merely a cost optimisation question.

Third, novel modalities are demanding manufacturing capability that most companies do not have. Cell and gene therapies, mRNA-based treatments, antibody-drug conjugates, and radioligand therapies each require specialised manufacturing infrastructure, quality systems, and operational expertise that is genuinely scarce globally. According to BPM, "the proliferation of novel modalities are putting unprecedented demands on life sciences companies' manufacturing capabilities," and "advanced therapies require specialised facilities, sophisticated quality systems, and highly trained personnel that are in limited supply." A company developing a CAR-T cell therapy or a next-generation ADC that lacks access to appropriate manufacturing capacity cannot commercially deliver its own pipeline asset, regardless of how successful the clinical trials were. Capacity has become a constraint on commercialisation, not merely a cost of goods consideration.

Fourth, the speed at which tariff and pricing policy is changing has compressed strategic planning horizons. Companies that were planning manufacturing footprints on five to ten year cycles are now being required to make decisions with implications for the next ten to fifteen years based on trade policies that are changing quarterly. The US Section 232 tariffs announced in April 2026, imposing 100% ad valorem duties on patented pharmaceutical products with 180 days until implementation for most importers, have made the question of where a product will be manufactured at BLA submission an active strategic decision that must be resolved during Phase 3, not after regulatory approval.

The UK as a Case Study: What Board-Level Manufacturing Priority Looks Like on the Ground

‍Nowhere is the translation of manufacturing from operational function to strategic priority more tangible than in the UK, where two major CDMO expansions announced within months of each other provide concrete evidence of what the global trend looks like in a specific geography.

FUJIFILM Biotechnologies Teesside: £400 Million, UK's Largest Single-Use Biologics CDMO Facility

‍On February 11, 2026, FUJIFILM Biotechnologies celebrated the grand opening of its expanded manufacturing site in Teesside, North-East England, backed by approximately £400 million in investment from FUJIFILM Corporation Japan. The expansion includes what the BDO bioTRAK database (as of October 2024) identifies as the largest single-use biopharmaceutical CDMO facility in the UK.

The 110,000 square foot manufacturing facility introduces 2,000 litre and 5,000 litre single-use bioreactors, creating a total manufacturing capacity of up to 19,000 litres for small- and mid-scale antibody production. Alongside the manufacturing expansion, the company opened a 102,200 square foot Bioprocess Innovation Centre UK (BIC UK), doubling the campus's laboratory footprint and delivering high-throughput and continuous process development capabilities, alongside expanded GMP quality control functions. The site supports development from early process development through to early clinical manufacturing and commercial biologics production, all in a single location.

The facility uses FUJIFILM Biotechnologies' kojoX modular approach to biomanufacturing, a strategic global initiative to harmonise technology, equipment, systems, and processes across its global network. Through this standardisation, Fujifilm's Teesside operations align with the company's Toyama facility in Japan and its sites in the United States and Denmark, enabling what Lars Petersen, President and CEO of FUJIFILM Biotechnologies, described as "enhanced scalability, speed to market, and cross-site technology transfer, helping to ensure reliable medicine supply for patients in the UK and globally." The facility's SymphonX downstream processing skid introduces an all-in-one equipment design to run all downstream unit operations across multiple scales, providing flexibility across fed-batch and continuous processes, a level of integrated downstream capability that is uncommon in CDMO facilities outside of specialist biologics manufacturers.

Toshihisa Iida, Director and Corporate Vice President of FUJIFILM Corporation, confirmed that over the past decade Fujifilm has invested more than £5 billion globally to grow its CDMO business. The Teesside site employs more than 960 people and the expansion received formal support from UK Health Innovation Minister Dr Zubir Ahmed, who stated that the investment helps deliver the UK government's Life Sciences Sector Plan, announced in July 2025. The facility is designed to be fully electric and harness renewable energy, aligning with FUJIFILM Biotechnologies' sustainability commitments.

Kindeva Drug Delivery Loughborough: 150,000 Square Foot UK Headquarters

‍On September 18, 2025, Kindeva, a global CDMO and drug delivery expert formerly part of 3M Drug Delivery Systems, officially opened its new UK headquarters at Charnwood Campus Science Innovation and Technology Park in Loughborough. The 150,000 square foot site offers a full range of drug development services from early-stage viability assessment, analytical method development, and CMC strategy through to commercial analysis. It is specifically designed to develop and test next-generation propellants (NGP) for metered-dose inhalers as the pharmaceutical industry prepares for the regulatory and environmental transition to more sustainable inhaler propellants, and represents a significant expansion in Kindeva's MDI manufacturing and development services.

The Loughborough site positions Kindeva, which employs more than 500 people across its two UK sites, as the UK headquarters for a company that serves some of the world's largest pharmaceutical companies on complex drug delivery and combination product challenges. The UK investment delivers on an earlier £33 million joint government and industry commitment, including support from the UK government to create more than 250 high-skilled jobs. Milton Boyer, CEO of Kindeva at the time of opening, said the launch "marks a significant milestone in Kindeva's growth strategy as we continue to innovate, scale, and expand our global capabilities."

Together, these two UK CDMO expansions are not isolated data points. They are part of a pattern that includes Lonza's £570 million UK biologics campus investments, the Life Sciences Innovative Manufacturing Fund commitments, AstraZeneca's £300 million Cambridge and Macclesfield investment announced in April 2026, and over £1.4 billion in broader pharmaceutical investment commitments made in the UK since December 2025.

What Board-Level Manufacturing Priority Changes in Practice

‍When pharmaceutical manufacturing moves from a function to a strategic priority, the practical consequences spread across the entire organisation.

Clinical development timelines are now planned with manufacturing scalability as a constraint from Phase 2, not post-Phase 3. Regulatory affairs strategy must account for where a product will be manufactured at the point of BLA or MAA submission and whether that location will remain strategically viable. M&A decisions include manufacturing footprint and capacity assessment as a primary valuation driver, not a due-diligence afterthought. Chief procurement officers are mapping supply and tariff risks at SKU level across APIs, raw materials, reagents, single-use components, and replacement parts. CDMOs are being selected not on price or geography alone but on regulatory track record, manufacturing technology platform, long-term capacity availability, and ability to support a programme continuously from clinical to commercial scale without requiring disruptive technology transfers.

The shift in CDMO relationship management is particularly significant. Matthew Holt, Co-Founder and Managing Director at Collaborative Sourcing, stated plainly in his 2026 manufacturing predictions: "In 2026, pharma companies will realise that a light-touch approach to supplier relationship management with CDMOs will become their biggest liability. They have outsourced the development and production, but they have lost oversight of the deeper supply chain." Holt argued that companies "must reclaim oversight of areas such as risk management, cost optimisation, quality, and ethical practices if they are to maintain quality and speed-to-market." This is a diagnosis of a structural problem that emerges precisely when manufacturing has been treated as an operational, rather than strategic, function.

The pharmaceutical industry has spent a generation optimising its supply chain for cost, relocating manufacturing to wherever it was cheapest to produce, and relying on global logistics to deliver products to any market. The costs of that optimisation, which were always present but manageable in a stable geopolitical environment, became intolerable during and after the COVID-19 pandemic. What is now being built in the UK, the US, and across Europe is the manufacturing infrastructure of a different strategic model: one in which agility, resilience, regulatory predictability, and proximity to key markets matter as much as unit cost. The boards that understood this first are already building the facilities. The boards that understand it now are placing the orders. The question for the industry in 2026 is how many are still waiting.

Sources: Pharma Manufacturing ("2026 is the year of pharma manufacturing, supply chain efficiencies"), Bain and Company pharmaceutical M&A report 2026, PharmaVoice ("4 takeaways from pharma's manufacturing boom"), Fierce Pharma ("Pharmas have promised $370B in US investments amid 2025's onshoring boom"), DCAT Value Chain Insights Big Pharma US Manufacturing Investment, Think Global Health (tracking pharma onshoring progress), FUJIFILM Biotechnologies press release February 11, 2026, European Pharmaceutical Review Fujifilm Teesside opening, Pharmaceutical Technology Fujifilm UK expansion analysis, Kindeva press release September 18, 2025, Kindeva Loughborough UK HQ reporting, PharmaSource ("The Great Reshoring: How $24.86 Billion Reshaped CDMO Manufacturing in 2025"), ZS Associates pharma industry outlook 2026, BPM 2026 life sciences outlook, Deloitte 2026 life sciences outlook, PharmaSource expert predictions for pharma manufacturing 2026, DSV geopolitical risk in pharmaceutical supply chains 2026, Insight Global pharmaceutical manufacturing expansion 2026, Bain and Company 2026 pharmaceutical M&A strategic advice.